Home › Companies › PALI

Palisade Bio

Market cap $181M 179.3M shares (10-Q, Nov 6, 2026) × $1.01 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

8 trackedQuarter catalyst calendar →
  1. PALI-2108 UC Ph2 start2H 2026PALI-2108 UC Ph2 start, 2H 2026, notable
  2. PALI-2108 CD IND filing2H 2026PALI-2108 CD IND filing, 2H 2026, notable
  3. BIOSECURE companies of concern listDec 18, 2026BIOSECURE companies of concern list, Dec 18, 2026, routine
  4. PALI-2108 UC trial start1H 2027PALI-2108 UC trial start, 1H 2027, notable
  5. PALI-2108 UC topline2H 2027PALI-2108 UC topline, 2H 2027, thesis-defining
  6. PALI-2108 CD interim2H 2027PALI-2108 CD interim, 2H 2027, material
  7. ASCENTRA-UC readout4Q 2027ASCENTRA-UC readout, 4Q 2027, material
  8. PALI-2108 CD toplineearly 2028PALI-2108 CD topline, early 2028, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

PALI-1908

Capital (as filed)

Cash
$114M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$11.8M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$114M cash, runway Q4 2027 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Palisade Bio, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Palisade Bio (PALI) - Scientific Deep Dive for PALI-2108 and Pipeline Products The prodrug engineering is real and the balance sheet funds the binary, but PDE4 failed its one controlled UC trial, Phase 2 doses are below the regimen that generated the clinical signal, and there is no issued U.S. patent under a ~$457M market cap.
  2. Watch UPDATE: Palisade Bio (PALI) - The Second Shot Gets Cleared FDA IND clearance for ASCENTRA-CD is a clean execution tick but does not advance or de-risk the ASCENTRA-UC Week 12 readout that constitutes the entire valuation; the dose discontinuity remains unresolved.
  3. Watch UPDATE: Palisade Bio (PALI) - The Trial Started, the Stock Kept Sliding First patient dosed and balance sheet intact, but the dose bridge remains unproven, a new single-source WuXi API supply risk emerged ahead of the December BIOSECURE list deadline, and the lower EV improves entry math without improving the drug's odds.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (27)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 10, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

19 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)